A Phase I, Double Blind, Placebo Controlled, Multiple Oral Dose, Safety, Tolerability, and Pharmacokinetic Study of KBP-7072 in Healthy Male and Female Subjects
Latest Information Update: 09 Sep 2021
At a glance
- Drugs Zifanocycline (Primary)
- Indications Bacterial infections
- Focus Adverse reactions
- Sponsors KBP Biosciences
- 30 Aug 2021 Status changed from recruiting to completed.
- 02 Sep 2020 New trial record